Estrella Immunopharma (ESLA) Net Cash Flow (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Net Cash Flow of $541112.0 for Q1 2026, up 209.22% year-over-year from $174993.8 in Q1 2025, and up 310.85% quarter-over-quarter from -$256629.0 in Q4 2025.
Estrella Immunopharma (ESLA) Net Cash Flow (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Net Cash Flow for 6 consecutive years, with $541112.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 209.22% year-over-year to $541112.0; the TTM figure through Mar 2026 stood at $1.5 million (up 109.38% YoY), while the FY2025 annual figure was $453065.0, up 105.57% from the prior year.
- Net Cash Flow improved to $541112.0 in Q1 2026 per ESLA's latest filing, from -$256629.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $19.7 million in Q3 2023 and bottomed at -$37.3 million in Q4 2022.
- Historically, Net Cash Flow has averaged -$1.5 million across 5 years, with a median of -$256629.0 in 2025.
- Annual changes were most pronounced in 2023 — Net Cash Flow soared 1886.8% — and 2024, when it tumbled 79726.41%.
- Estrella Immunopharma's Net Cash Flow stood at -$37.3 million in 2022, then surged by 137.37% to $13.9 million in 2023, then slumped by 123.32% to -$3.2 million in 2024, then soared by 92.1% to -$256629.0 in 2025, then surged by 310.85% to $541112.0 in 2026.
- Business Quant data shows ESLA's Net Cash Flow at $541112.0 in Q1 2026, -$256629.0 in Q4 2025, and $310016.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Estrella Immunopharma | 32.24 Mn | 32.10 Mn | - | -1.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.80 Mn |
| Jun 30, 2026 | -1.80 Mn |
| Mar 31, 2026 | 541,112.00 |
| Mar 31, 2026 | 541,112.00 |
| Dec 31, 2025 | -256,629.00 |
| Dec 31, 2025 | -256,629.00 |
| Sep 30, 2025 | 310,016.00 |
| Sep 30, 2025 | 310,016.00 |
| Jun 30, 2025 | 895,121.00 |
| Jun 30, 2025 | 895,121.00 |
| Mar 31, 2025 | -495,443.00 |
| Mar 31, 2025 | -495,443.00 |
| Dec 31, 2024 | -3.25 Mn |
| Dec 31, 2024 | -3.25 Mn |
| Sep 30, 2024 | -7.25 Mn |
| Sep 30, 2024 | -7.25 Mn |
| Jun 30, 2024 | -4.88 Mn |
| Jun 30, 2024 | -4.88 Mn |
| Mar 31, 2024 | -4.32 Mn |
| Mar 31, 2024 | -4.32 Mn |